Can a new painkiller beat placebo after foot surgery?

NCT ID NCT07807644

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an experimental painkiller called GRT7040 in about 400 adults who have acute pain after bunionectomy, a common foot surgery. Participants receive one of three doses of GRT7040, a placebo, or a standard painkiller (hydrocodone/acetaminophen) for up to 48 hours after surgery. Researchers measure pain relief using a 0-to-10 scale and track side effects to see if GRT7040 is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GRT7040, an experimental painkiller tested at three doses
What this could lead to
If GRT7040 works, it could offer a new option for managing moderate-to-severe acute pain after surgery, possibly with fewer side effects than current opioids.
What could go wrong
This is an early Phase 2 trial, so GRT7040 may not prove more effective than placebo or may cause unexpected side effects. Results will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults scheduled for a primary unilateral bunionectomy with distal first metatarsal osteotomy and internal fixation under regional anesthesia. * Able and willing to provide informed consent and comply with study procedures. * Body weight ≥50 kg and BMI 18 to 40 kg/m². * Medically fit for surgery and study treatment based on medical history, physical examination, ECG, vital signs, and laboratory assessments. * Meets protocol-specified contraception requirements. * After surgery, reports moderate to severe pain (Verbal Rating Scale) with a Numeric Pain Rating Scale (NPRS) score ≥4 within 9 hours after removal of the popliteal sciatic block. * Able to follow commands and has complied with protocol-required perioperative analgesic guidelines. Exclusion Criteria * Clinically significant medical conditions or laboratory abnormalities that could increase risk or interfere with study assessments. * Major surgery within 6 months prior to screening or anticipated need for major surgery during the study. * Prior bunionectomy or related surgery on either applicable foot. * Peripheral neuropathy affecting the legs. * Clinically significant cardiac disease, arrhythmias, QT prolongation risk, or abnormal ECG findings. * Sleep apnea requiring positive airway pressure therapy. * American Society of Anesthesiologists (ASA) physical status classification ≥3. * Contraindication, intolerance, allergy, or unwillingness to receive study-related analgesics, NSAIDs, acetaminophen/hydrocodone, local anesthetics, or study drug components. * Participation in another interventional clinical trial within the protocol-defined exclusion period. * Significant renal impairment, hepatic impairment, positive HIV, hepatitis B, or hepatitis C tests. * History of substance abuse or addiction within the previous 3 years or positive drug/alcohol screening as specified by the protocol. * Blood or plasma donation exceeding protocol limits before screening. * Pregnant, breastfeeding, planning pregnancy during the study, or unwilling to comply with contraception requirements. * Postoperative factors precluding randomization, including unsuccessful popliteal block placement, surgical complications, non-adherence to postoperative analgesic requirements, or medical complications during surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.